Aethlon Medical (NASDAQ:AEMD) Posts Earnings Results, Misses Expectations By $2.04 EPS

Aethlon Medical (NASDAQ:AEMD) issued its quarterly earnings results on Wednesday. The medical equipment provider reported ($3.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.70) by ($2.04), FiscalAI reports.

Aethlon Medical Stock Up 6.6%

AEMD traded up $0.32 during trading on Friday, hitting $5.06. 15,708 shares of the company’s stock were exchanged, compared to its average volume of 102,396. The business’s 50 day moving average is $6.38 and its two-hundred day moving average is $14.95. The stock has a market cap of $1.31 million, a P/E ratio of -0.14 and a beta of 1.83. Aethlon Medical has a fifty-two week low of $4.02 and a fifty-two week high of $84.40.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on AEMD. Wall Street Zen raised Aethlon Medical to a “sell” rating in a report on Saturday, August 30th. HC Wainwright reaffirmed a “neutral” rating on shares of Aethlon Medical in a report on Thursday, August 14th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aethlon Medical in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Reduce” and an average target price of $560.00.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.